Comparison of raloxifene and alendronate on markers of cardiovascular health in postmenopausal women with osteoporosis

被引：0
|
作者：
Reginster, JY
Adachi, JR
Qu, Y
Siddhanti, S
Keech, C
机构：
[1] Univ Liegravege, Bone & Cartilage Metab Unit, Liegravege, Belgium
[2] Univ Liegravege, Dept Epidemiol & Publ Hlth, Liegravege, Belgium
[3] McMaster Univ, Dept Med, St Josephs Hosp, Hamilton, ON, Canada
[4] Lilly Res Labs, Indianapolis, IN USA
来源：
OSTEOPOROSIS INTERNATIONAL | 2003年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S42 / S42
页数：1
相关论文
共 50 条
  • [1] Comparison of raloxifene and alendronate on markers of cardiovascular health in postmenopausal women with osteoporosis.
    Adachi, JD
    Reginster, J
    Qu, Y
    Siddhanti, S
    Keech, C
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S379 - S379
  • [2] Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis
    Sanad, Z.
    Ellakwa, H.
    Desouky, B.
    [J]. CLIMACTERIC, 2011, 14 (03) : 369 - 377
  • [3] Effects of raloxifene and alendronate on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis
    Johnell, O
    Lu, Y
    Seeman, E
    Reginster, J
    Scheele, W
    [J]. OSTEOPOROSIS INTERNATIONAL, 2000, 11 : S184 - S184
  • [4] Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women
    Ringe, J. D.
    Christodoulakos, G. E.
    Mellstroem, D.
    Petto, H.
    Nickelsen, T.
    Marin, F.
    Pavo, I.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (11) : 2677 - 2687
  • [5] Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis
    Johnell, O
    Scheele, WH
    Lu, YL
    Reginster, JY
    Need, AG
    Seeman, E
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (03): : 985 - 992
  • [6] Effects of raloxifene on markers of cardiovascular risk in non-Caucasian postmenopausal women with osteoporosis
    Johnson, S
    Kulkarni, P
    Qu, Y
    Ciaccia, A
    Keech, C
    [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2003, 10 (06): : 567 - 567
  • [7] Individualizing therapy to prevent postmenopausal osteoporosis: A comparison of hormone therapy, alendronate, and raloxifene
    Col, NF
    Pauker, SG
    Goldberg, RJ
    Eckman, MH
    Orr, RK
    Ross, EM
    Wong, JB
    [J]. MEDICAL DECISION MAKING, 1998, 18 (04) : 467 - 467
  • [8] Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis
    Ensrud, K
    Genazzani, AR
    Geiger, MJ
    McNabb, M
    Dowsett, SA
    Cox, DA
    Barrett-Connor, E
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (04): : 520 - 527
  • [9] Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate
    R. A. Wermers
    C. P. Recknor
    F. Cosman
    L. Xie
    E. V. Glass
    J. H. Krege
    [J]. Osteoporosis International, 2008, 19 : 1055 - 1065
  • [10] Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate
    Wermers, R. A.
    Recknor, C. P.
    Cosman, F.
    Xie, L.
    Glass, E. V.
    Krege, J. H.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2008, 19 (07) : 1055 - 1065
12345